Catalent Inc. (NYSE: CTLT) stock jumped 0.15% on Monday to $39.93 against a previous-day closing price of $39.87. With 1.94 million shares changed hands, the volume of the stock remained lighter than its average volume of 2.51 million shares. During the session, the Drug Manufacturers – Specialty & Generic company that operates in wider Healthcare sector, reached to the highest price of $40.74 whereas the lowest price it dropped to was $39.45. The 52-week range on CTLT shows that it touched its highest point at $74.49 and its lowest point at $31.45 during that stretch. It currently has a 1-year price target of $48.38. Beta for the stock currently stands at 1.29.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of CTLT was up-trending over the past week, with a rise of 20.63%, but this was down by -5.29% over a month. Three-month performance dropped to -10.09% while six-month performance rose 6.45%. The stock lost -5.09% in the past year, while it has lost -11.29% so far this year. A look at the trailing 12-month EPS for CTLT yields -5.23 with Next year EPS estimates of 1.68. For the next quarter, that number is -0.02. This implies an EPS growth rate of -25.74% for this year and 127.40% for next year.
Float and Shares Shorts:
On Oct 30, 2023, short shares totaled 10.1 million, which was 5.60% higher than short shares on Sep 28, 2023. In addition to Mr. John J. Greisch M.B.A. as the firm’s Executive Chairman of the Board, Mr. Alessandro Maselli serves as its President, CEO & Director.
Through their ownership of 106.31% of CTLT’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 64.94% of CTLT, in contrast to 44.08% held by mutual funds. Shares owned by individuals account for 17.82%. As the largest shareholder in CTLT with 10.94% of the stake, The Vanguard Group, Inc. holds 19,728,021 shares worth 19,728,021. A second-largest stockholder of CTLT, Capital Research & Management Co, holds 17,981,520 shares, controlling over 9.98% of the firm’s shares. Janus Henderson Investors US LLC is the third largest shareholder in CTLT, holding 14,602,803 shares or 8.10% stake. With a 3.25% stake in CTLT, the T Rowe Price Mid Cap Growth Fund is the largest stakeholder. A total of 5,862,920 shares are owned by the mutual fund manager. The Vanguard Total Stock Market ETF, which owns about 2.98% of CTLT stock, is the second-largest Mutual Fund holder. It holds 5,362,326 shares valued at 184.41 million. American Funds Capital World Grow holds 2.59% of the stake in CTLT, owning 4,675,978 shares worth 160.81 million.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for CTLT since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With CTLT analysts setting a high price target of $58.00 and a low target of $40.00, the average target price over the next 12 months is $48.77. Based on these targets, CTLT could surge 45.25% to reach the target high and rise by 0.18% to reach the target low. Reaching the average price target will result in a growth of 22.14% from current levels.
Summary of Insider Activity:
Insiders traded CTLT stock several times over the past three months with 32 Buys and 14 Sells. In these transactions, 138,653 shares were bought while 6,589 shares were sold. The number of buy transactions has increased to 48 while that of sell transactions has risen to 35 over the past year. The total number of shares bought during that period was 294,732 while 15,468 shares were sold.